Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1984 1
1985 2
1986 1
1987 1
1989 3
1990 1
1992 2
1993 1
1995 2
2010 1
2011 1
2017 1
2018 2
2020 5
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant É, Bizec JL, Bernier C, Quéré G, Amrane K, Gaye E, Lucia F, Burte E, Chouaid C, Robinet G. Geier M, et al. Among authors: bizec jl. Cancer Med. 2020 Oct;9(19):6923-6932. doi: 10.1002/cam4.3120. Epub 2020 May 15. Cancer Med. 2020. PMID: 32412157 Free PMC article.
Hiccup in adults: an overview.
Launois S, Bizec JL, Whitelaw WA, Cabane J, Derenne JP. Launois S, et al. Among authors: bizec jl. Eur Respir J. 1993 Apr;6(4):563-75. Eur Respir J. 1993. PMID: 8491309 Review.
[Chronic hiccups].
Cabane J, Desmet V, Derenne JP, Similowski T, Launois S, Bizec JL, Orcel B. Cabane J, et al. Among authors: bizec jl. Rev Med Interne. 1992 Nov;13(6):454-9. doi: 10.1016/s0248-8663(05)81547-4. Rev Med Interne. 1992. PMID: 1344930 French.
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D. Payen T, et al. Among authors: bizec jl. Respir Med Res. 2021 Nov;80:100795. doi: 10.1016/j.resmer.2020.100795. Epub 2020 Nov 1. Respir Med Res. 2021. PMID: 34242973
[Hiccups in adults].
Bizec JL, Launois S, Bolgert F, Lamas G, Chollet R, Derenne JP. Bizec JL, et al. Rev Mal Respir. 1995;12(3):219-29. Rev Mal Respir. 1995. PMID: 7638419 Review. French.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. Amrane K, et al. Among authors: bizec jl. Cancer Med. 2020 Apr;9(7):2309-2316. doi: 10.1002/cam4.2806. Epub 2020 Feb 5. Cancer Med. 2020. PMID: 32022459 Free PMC article. Clinical Trial.
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
Adams CM, Anderson K, Artman G 3rd, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y. Adams CM, et al. Among authors: bizec jc. J Med Chem. 2018 Feb 22;61(4):1622-1635. doi: 10.1021/acs.jmedchem.7b01731. Epub 2018 Feb 5. J Med Chem. 2018. PMID: 29400470
26 results